About Pediatric Pharmaceuticals
Pediatric Pharmaceuticals, Inc. (PPI) was formed to develop and market unique pharmaceutical products designed to fulfill the needs of the medical community. Its first product CAFCIT, caffeine citrate for apnea of prematurity, received FDA approval in September 1999 and is now on the market throughout the U.S. nn PPI plans to target the development of pharmaceuticals, many of which will qualify as orphan drugs capable of obtaining the financial/patent benefits of the Orphan Drug Act. Major drug companies are usually not interested in these products because of their relatively small sales potential. The Company also feels that once certain specialty products are approved, they may find a larger audience through use in other indications. nnn As long term strategy, PPI plans to identify and financially support selected university and hospital research projects that offer strong potential as major pediatric and adult products. This investment program should provide the Company with a stream of new and innovative products as well as foster formal relationships with leading medical research centers.